Cargando…

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma

BACKGROUND/AIMS: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). METHODS: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Incheon, Lee, Jae Geun, Choi, Sung Hoon, Kim, Hyun Jeong, Han, Dai Hoon, Choi, Gi Hong, Kim, Myoung Soo, Choi, Jin Sub, Kim, Soon Il, Joo, Dong Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524068/
https://www.ncbi.nlm.nih.gov/pubmed/34293849
http://dx.doi.org/10.3350/cmh.2021.0038
_version_ 1784585433188925440
author Kang, Incheon
Lee, Jae Geun
Choi, Sung Hoon
Kim, Hyun Jeong
Han, Dai Hoon
Choi, Gi Hong
Kim, Myoung Soo
Choi, Jin Sub
Kim, Soon Il
Joo, Dong Jin
author_facet Kang, Incheon
Lee, Jae Geun
Choi, Sung Hoon
Kim, Hyun Jeong
Han, Dai Hoon
Choi, Gi Hong
Kim, Myoung Soo
Choi, Jin Sub
Kim, Soon Il
Joo, Dong Jin
author_sort Kang, Incheon
collection PubMed
description BACKGROUND/AIMS: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). METHODS: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. RESULTS: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). CONCLUSIONS: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.
format Online
Article
Text
id pubmed-8524068
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-85240682021-10-29 Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma Kang, Incheon Lee, Jae Geun Choi, Sung Hoon Kim, Hyun Jeong Han, Dai Hoon Choi, Gi Hong Kim, Myoung Soo Choi, Jin Sub Kim, Soon Il Joo, Dong Jin Clin Mol Hepatol Original Article BACKGROUND/AIMS: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). METHODS: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. RESULTS: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). CONCLUSIONS: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study. The Korean Association for the Study of the Liver 2021-10 2021-07-23 /pmc/articles/PMC8524068/ /pubmed/34293849 http://dx.doi.org/10.3350/cmh.2021.0038 Text en Copyright © 2021 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kang, Incheon
Lee, Jae Geun
Choi, Sung Hoon
Kim, Hyun Jeong
Han, Dai Hoon
Choi, Gi Hong
Kim, Myoung Soo
Choi, Jin Sub
Kim, Soon Il
Joo, Dong Jin
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
title Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
title_full Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
title_fullStr Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
title_full_unstemmed Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
title_short Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
title_sort impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524068/
https://www.ncbi.nlm.nih.gov/pubmed/34293849
http://dx.doi.org/10.3350/cmh.2021.0038
work_keys_str_mv AT kangincheon impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT leejaegeun impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT choisunghoon impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT kimhyunjeong impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT handaihoon impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT choigihong impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT kimmyoungsoo impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT choijinsub impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT kimsoonil impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma
AT joodongjin impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma